BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced initial positive results from a pilot study of its pain management drug candidate, Probudur™. The aim of the study was to ascertain whether Probudur can reduce pain behaviors in a rat model of incisional pain. “While the data from these studies will be further analyzed, these positive results are consistent with what we at Virpax have previously observed,” said Gerald W. Bruce, CEO of Virpax Pharmaceuticals. The company is initially seeking FDA approval for two prescription drug candidates, Probudur and Envelta, employing patented drug delivery platforms. These initial positive results from the Probudur pilot study represent a significant step forward for Virpax in its mission to develop effective, non-addictive pain management solutions.

Source: Forbes February 12, 2024 14:53 UTC